Company news

Cue Biopharma, Inc. news in 2026

Cue Biopharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

September 20, 2026

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

August 3, 2026

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

July 13, 2026

Cue Biopharma Announces $50.0 Million Private Placement

July 9, 2026

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

June 2, 2026

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

May 21, 2026

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

May 14, 2026

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026

Cue Biopharma Announces $30 Million Private Placement

April 30, 2026

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

April 30, 2026

Cue Biopharma Announces 1-for-30 Reverse Stock Split

April 22, 2026

Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

April 14, 2026

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

April 7, 2026

Cue Biopharma Announces CEO Transition

March 26, 2026

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

March 25, 2026

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 16, 2026

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

March 8, 2026

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

February 17, 2026

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

February 12, 2026

Decks in 2026